5 Stocks To Watch For Gains Next Week [View article]
Compare RAD's debt to that of WAG and CVS, it's not that bad. Sure, the company does have debt, but its valued more than accounts for its debt position. With the company profitable it can pay down the large debt. 1% profit margin on $25 billion of revenue equals a lot of income!
5 Stocks To Watch For Gains Next Week [View article]
Honestly, I have considered re-stocking fees but assume they are incorporated into guidance. I have never thought about re-negotiations of generic distribution. It's a great point and is something that I will explore. Good question/observation
5 Stocks To Watch For Gains Next Week [View article]
That's great! The (10-10-10) is an insider secret to those who bought the book. Its a great tool for finding fair value in established companies. Price/Sales is one of my favorite metrics..
5 Stocks To Watch For Gains Next Week [View article]
It was a psychological response. I call it the "HOG effect", when a stock trades illogically lower after good earnings. It is almost ALWAYS a great buying opportunity
5 Stocks To Watch For Gains Next Week [View article]
Amarin is the only company in the market where you can give a bullish outlook and still have radical longs say something negative. It's almost 1:00 AM my time, I address your comment on tomorrow (or Monday).
5 Stocks To Watch For Gains Next Week [View article]
I like to use price/sales over P/E because margins can always be improved upon. I'd rather invest in a massive company with room for improvements than a smaller company that has stretched its margins.
You can't really compare RAD to SVU because they are in two different industries (pharmacy/grocery). Kroger trades with a price/sales of 0.19 vs SVU having 0.18 (remember SVU is a much smaller company now). Therefore, SVU is about equal value to Kroger, yet nowhere near as efficient.
RAD still has a lot of room to improve margins, is now expecting consistent profits, and is 7 times cheaper than Walgreens.
Interviewing Dr. Losordo: The Promising Development Of CD34 Cells [View article]
Robert I really hope you are joking. Dr Losordo is working with NBS on the scientific advisory board, which is a an advisory role not employment. He left Baxter to pursue his clinical practice to bring novel cell therapies like NeoStem’s products into clinic. See his bio below…absolutely one of the best people in regenerative medicine.
Dr. Douglas W. Losordo, M.D., serves as the Chief of Cardiovascular Research of St. Elizabeth's Medical Center in Boston. Dr. Losordo serves as the Director of the Catheterization Laboratory at Caritas St. Elizabeth's Medical Center. He serves as Principal Investigator in many grant research projects and has published widely, contributing to more than 300 professional articles, abstracts and book chapters in recent years. He is a leading investigator in the field of cardiovascular research and has collaborated with AnorMED on both the transplant and tissue repair programs for AMD3100. He holds grant support to further the study on gene and cell therapy for heart vascular diseases. He serves as Director of the Feinberg Cardiovascular Research Institute and Program in Cardiovascular Regenerative Medicine. He has been a Member of Clinical Advisory Board at ReNeuron Group plc since February 2010. He serves as a Member of Scientific Advisory Board at Juventas Therapeutics, Inc. He has been Member of the Scientific Advisory Board of Neostem, Inc. since November 8, 2006. He served as a Scientific Advisor of Helix Biotherapeutic Delivery for BioCardia, Inc. Dr. Losordo served as a Member of the Scientific Advisory Board at AnorMED Inc. since February 11, 2004. He serves as an Associate Professor of Medicine at Tufts University School of Medicine and Professor of Heart Research at Northwestern University's Feinberg School of Medicine. He also serves on the editorial boards of the Journal of the American College of Cardiology, Circulation Research and Circulation, which includes stem Cells, Vascular Medicine and Circulation Research. Dr. Losordo also serves on the Committees of the American College of Cardiology, the American Diabetes Association and the American Society of Gene Therapy, where he chairs the Cardiovascular Gene Therapy Committee and is a Fellow or Member of many national professional organizations. He served as Co-chairman and Member of Steering Committee of Corautus Genetics Inc. Dr. Losordo is board-certified in internal medicine, cardiovascular disease, and interventional cardiology and is a Fellow of the American College of Cardiology, the American Heart Association, the American Association for the Advancement of Science, the American College of Physicians, the American College of Chest Physicians, and the US Society for Cardiac Angiography and Interventions. Dr. Losordo's major research interests encompass angiogenesis, vasculogenesis, progenitor, adult stem cells, tissue repair, regeneration, and vascular biology. Dr. Losordo has also trained numerous scientists and physician scientists from around the world. Dr. Losordo received his Medical Degree from the University of Vermont. Dr. Losordo completed an internship, residency and fellowship at St. Elizabeth's Medical, Boston, Massachusetts.
5 Stocks To Watch For Gains Next Week [View article]
Check out the rally on SNTS. it pulls back then trends higher to new highs. The market will do the same but as long as new highs are reached with every uptrend this rally will continue.
5 Stocks To Watch For Gains Next Week [View article]
It surprised me. I knew they would have to raise money but didn't know it would be this soon, nor do I know the thought process behind the decision. This money will give the company time for PCT to reach profitability and to reach full enrollment. In these type of companies the investment is for the future. I typically don't mind dilution so long as the upside Remains strong relative to market valuation
5 Stocks To Watch For Gains Next Week [View article]
You have to figure OTC fish products. There will be a lot of people who believe that it's not worth the prescription. I think $1.5 billion is generous considering the last year
5 Stocks To Watch For Gains Next Week [View article]
1% profit margin on $25 billion of revenue equals a lot of income!
5 Stocks To Watch For Gains Next Week [View article]
5 Stocks To Watch For Gains Next Week [View article]
5 Stocks To Watch For Gains Next Week [View article]
5 Stocks To Watch For Gains Next Week [View article]
5 Stocks To Watch For Gains Next Week [View article]
5 Stocks To Watch For Gains Next Week [View article]
You can't really compare RAD to SVU because they are in two different industries (pharmacy/grocery). Kroger trades with a price/sales of 0.19 vs SVU having 0.18 (remember SVU is a much smaller company now). Therefore, SVU is about equal value to Kroger, yet nowhere near as efficient.
RAD still has a lot of room to improve margins, is now expecting consistent profits, and is 7 times cheaper than Walgreens.
5 Stocks To Watch For Gains Next Week [View article]
Interviewing Dr. Losordo: The Promising Development Of CD34 Cells [View article]
Interviewing Dr. Losordo: The Promising Development Of CD34 Cells [View article]
Dr. Douglas W. Losordo, M.D., serves as the Chief of Cardiovascular Research of St. Elizabeth's Medical Center in Boston. Dr. Losordo serves as the Director of the Catheterization Laboratory at Caritas St. Elizabeth's Medical Center. He serves as Principal Investigator in many grant research projects and has published widely, contributing to more than 300 professional articles, abstracts and book chapters in recent years. He is a leading investigator in the field of cardiovascular research and has collaborated with AnorMED on both the transplant and tissue repair programs for AMD3100. He holds grant support to further the study on gene and cell therapy for heart vascular diseases. He serves as Director of the Feinberg Cardiovascular Research Institute and Program in Cardiovascular Regenerative Medicine. He has been a Member of Clinical Advisory Board at ReNeuron Group plc since February 2010. He serves as a Member of Scientific Advisory Board at Juventas Therapeutics, Inc. He has been Member of the Scientific Advisory Board of Neostem, Inc. since November 8, 2006. He served as a Scientific Advisor of Helix Biotherapeutic Delivery for BioCardia, Inc. Dr. Losordo served as a Member of the Scientific Advisory Board at AnorMED Inc. since February 11, 2004. He serves as an Associate Professor of Medicine at Tufts University School of Medicine and Professor of Heart Research at Northwestern University's Feinberg School of Medicine. He also serves on the editorial boards of the Journal of the American College of Cardiology, Circulation Research and Circulation, which includes stem Cells, Vascular Medicine and Circulation Research. Dr. Losordo also serves on the Committees of the American College of Cardiology, the American Diabetes Association and the American Society of Gene Therapy, where he chairs the Cardiovascular Gene Therapy Committee and is a Fellow or Member of many national professional organizations. He served as Co-chairman and Member of Steering Committee of Corautus Genetics Inc. Dr. Losordo is board-certified in internal medicine, cardiovascular disease, and interventional cardiology and is a Fellow of the American College of Cardiology, the American Heart Association, the American Association for the Advancement of Science, the American College of Physicians, the American College of Chest Physicians, and the US Society for Cardiac Angiography and Interventions. Dr. Losordo's major research interests encompass angiogenesis, vasculogenesis, progenitor, adult stem cells, tissue repair, regeneration, and vascular biology. Dr. Losordo has also trained numerous scientists and physician scientists from around the world. Dr. Losordo received his Medical Degree from the University of Vermont. Dr. Losordo completed an internship, residency and fellowship at St. Elizabeth's Medical, Boston, Massachusetts.
5 Stocks To Watch For Gains Next Week [View article]
5 Stocks To Watch For Gains Next Week [View article]
5 Stocks To Watch For Gains Next Week [View article]
5 Stocks To Watch For Gains Next Week [View article]
5 Stocks To Watch For Gains Next Week [View article]